Clinical Trial: Continued Access to PREVAIL (CAP2)

Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional

Official Title: Continued Access to PREVAIL (CAP2)- WATCHMAN Left Atrial Appendage (LAA) Closure Technology

Brief Summary: To provide additional information about the safety and efficacy of the WATCHMAN LAA Closure Technology

Detailed Summary:
Sponsor: Boston Scientific Corporation

Current Primary Outcome: Incidence of stroke leading to significant disability/death [ Time Frame: up to 5 years ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Boston Scientific Corporation

Dates:
Date Received: November 6, 2012
Date Started: September 2012
Date Completion: February 2019
Last Updated: July 18, 2016
Last Verified: July 2016